LEVERAGE EXPERTISE

AbbVie aims to leverage our expertise and resources to address global health needs and improve standards of care.




We bring deep expertise and passion to our work addressing numerous health challenges around the world. In 2013, more than 55% of U.S. volunteer hours went towards projects that utilized employees’ professional skills and expertise. For example, employees in our legal team provided 1,000+ hours of pro bono service in 2013. 

AbbVie is committed to addressing the world's recognized health challenges, including neglected tropical diseases (NTDs), infections that disproportionately impact the world's poor and marginalized populations. According to the World Health Organization, more than 1 billion people suffer from one or more of these conditions.

The Executive Council on Neglected Diseases coordinates efforts across the company to contribute innovative technologies, compounds for screening, and our scientific expertise. In 2013, more than 100 of AbbVie’s most experienced scientists contributed their expertise to helping solve NTDs through drug development projects, advisory boards and compound screening partner organizations. We have provided a large library of diverse chemicals to screen against many NTDs, collaborating with the following partners:


Drugs for Neglected Diseases initiative (DNDi)
+

AbbVie is supplying thousands of our compounds to be screened for activity against Leishmania, Chagas Disease and helminth infections. This relationship expanded in 2012 to include a four-year joint research and nonexclusive licensing agreement. The joint venture provides DNDi access to selected classes of AbbVie's proprietary molecules, identified from the above screens, and accompanying data to guide the search for improved treatments. Any products developed as a result of this partnership will be provided to endemic countries by DNDi at the lowest sustainable price to ensure the greatest patient access. Learn more at www.dndi.org.


Gates Foundation TB Drug Accelerator (TBDA) consortium
+

As a founding member of TBDA, AbbVie has provided over 100,000 of our compounds for screening against replicating TB. Active compounds from these screens will be shared within the consortium to speed the identification of most promising approaches to shorten and improve the quality of TB therapy. AbbVie scientists are very engaged with this partnership, providing cheminformatics support and characterizing lead compounds from other TBDA partners in addition to the above screening activities.


TB Alliance
+

AbbVie scientists provide technical consulting through the TB Alliance Scientific Advisory Council, while new compounds are synthesized at AbbVie and then screened against both replicating and latent TB at the University of Illinois, Chicago. Learn more at www.tballiance.org.


Medicines for Malaria Venture (MMV)
+

AbbVie is working closely with MMV to support two preclinical development programs of novel antimalarials. Learn more at www.mmv.org.


University Partnerships
+

We work with leading research institutions including Liverpool School of Tropical Medicine (Anti-Wolbachia Consortium, see www.a-wol.com), University of Washington, University of Sussex and University of Dundee (Drug Discovery Unit) on NTD screening and research. In addition, we provide laboratory facilities and mentor student interns under a program sponsored by Franciscan University of Steubenville (Franciscan Institute for World Health).


Government Partnerships
+

AbbVie employees mentor students, sharing their expertise with the next generation of innovators, through our sponsorship of the Brazilian Scientific Mobility program. It grants Brazilian students opportunities to study STEM fields in the U.S. and promotes knowledge sharing and capacity building by investing in future leaders.

In Argentina, AbbVie has partnered with the Ministry of Health of Jujuy since 2012 to provide educational materials to teachers on the prevention of Chagas and Dengue.


1386093634802

AbbVie Foundation Treating Neglected Tropical Diseases
+

The AbbVie Foundation, a non-profit charitable organization, supports advancing progress against NTDs. Its $3 million combined commitment to two organizations has seen:

  • Eight thousand health workers deliver Mass Drug Administration to more than two million people in Haiti at the end of 2013. This project, addressing lymphatic filariasis in Haiti, is run by the University of Notre Dame. We are working together to address this debilitating illness that affects up to 60% in some areas of the country. The AbbVie Foundation’s support for this University of Notre Dame initiative also addresses the 58 percent of Haitian children who suffer from iodine deficiency by focusing on sustainable production of fortified salt. In 2012, 250,000 pounds of co-fortified salt was distributed, helping eliminate iodine deficiency among children in the country.
 
  • Ninety-nine percent of people with Buruli ulcer (a severe skin ulceration) who are treated completed the full antibiotic treatment needed in the Ivory Coast. This is accomplished through treatment, education campaigns and health care professional training as part of a three-year partnership with MAP International.

Industry Collaboration to Combat Neglected Diseases
+

Along with these public-private partnerships, we joined 12 other health care companies, the Bill & Melinda Gates Foundation, World Bank, several leading non-governmental organizations, and the governments of several large countries in a new, coordinated campaign to eliminate or control 10 NTDs by the year 2020. In the largest coordinated effort to date to combat NTDs, AbbVie and the coalition partners announced that we will collectively sustain or expand existing medicine donation programs; further share expertise and compounds to accelerate the development of new medicines; and strengthen medicine distribution programs. To learn more about AbbVie's support for the London Declaration on NTDs, visit www.unitingtocombatntds.org.


YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?

EXIT ABBVIE.COM

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site.

As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to continue to this product-specific site?

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?